ArticleJAMA network open2021

Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma.

Dan Su et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.